Abstract
Objective To evaluate effects of interleukin-36α (IL-36α) on psoriasiform skin lesions and C-C motif chemokine ligand 20 (CCL20) expression in mice. Methods Totally, 30 BALB/c female mice were randomly and equally divided into 3 groups: control group treated with topical vaseline cream on the shaved back and intracutaneous injection with phosphate buffer saline (PBS) , model group treated with topical imiquimod cream on the shaved back and intracutaneous injection with PBS, experimental group treated with topical imiquimod cream on the shaved back and intracutaneous injection with IL-36α solution. Psoriasis area severity index (PASI) was used to evaluate changes of psoriasiform skin lesions in mice, and light microscopy to observe morphological changes of skin lesions and to measure the thickness of the epidermis. Real-time fluorescence-based quantitative PCR (qRT-PCR) and Western blot analysis were performed to determine the expression of IL-36α in skin lesions in the control group and model group, and qRT-PCR, Western blot analysis and immunohistochemical study to evaluate changes of CCL20 levels in skin lesions. Results The model group showed significantly increased mRNA (∆Ct value: 0.0195 ± 0.0059) and protein expression (3.922 ± 0.248) of IL-36α compared with the control group (mRNA: 0.0012 ± 0.0004, P < 0.05; protein: 0.690 ± 0.025, P < 0.05) . The mRNA and protein expression of CCL20 were significantly higher in the experimental group than those in the model group (mRNA: 2.152 ± 0.793 vs. 0.999 ± 0.178; protein: 0.397 ± 0.033 vs. 0.145 ± 0.030; both P < 0.05) , and higher in the model group than those in the control group (mRNA: 0.378 ± 0.075; protein: 0.025 ± 0.009; both P < 0.05) . Immunohistochemical study showed that the expression intensity of CCL20 in skin lesions significantly increased in the experimental group compared with that in the model group (Z= 2.294, P < 0.05) . Conclusion IL-36α may aggravate psoriasiform skin inflammation in mice by promoting CCL20 expression. Key words: Psoriasis; Disease models, animal; Chemokine CCL20; Imiguimod; Interleukin-36α
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
